Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 1,601–1,610 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 1601
- Medicine slug
- valganciclovir
- Compared field
- proteinBinding
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 25
- Source count
- 24
- Agreement rate
- 0.708333
- Recorded readings
1 to 2%
- Numeric value
- 1
- Unit
- %
- Source records
- 17
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 17 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2e8a4d62-2098-4ffe-a154-e45cfdfe6c4c (opens source in a new tab)
Valganciclovir label
Version not recorded · Effective date not recorded
to 3.0h Food effect (high fat meal/fasting): PK parameter ratio and 90% confidence interval a C max : 1.14 (0.95, 1.36) AUC: 1.30 (1.07, 1.51) a T max : ↔ Distribution % Bound to human plasma proteins ( ex vivo ) Unknown 1 to 2% over 0.5 to 51 mcg/mL Cerebrospinal fluid penetration Unknown Yes Metabolism Hydrolyzed by intestinal and liver esterases No significant metabolism Elimination Dose propo
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:614ff447-7e5f-4ea6-ba85-ec1f6497b360 (opens source in a new tab)
Valganciclovir label
Version not recorded · Effective date not recorded
to 3.0h Food effect (high fat meal/fasting): PK parameter ratio and 90% confidence interval a C max : 1.14 (0.95, 1.36) AUC: 1.30 (1.07, 1.51) a T max : ↔ Distribution % Bound to human plasma proteins ( ex vivo ) Unknown 1 to 2% over 0.5 to 51mcg/mL Cerebrospinal fluid penetration Unknown Yes Metabolism Hydrolyzed by intestinal and liver esterases No significant metabolism Elimination Dose propor
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:89a934f0-85a3-44c1-82e5-d09d1738e08d (opens source in a new tab)
Valganciclovir label
Version not recorded · Effective date not recorded
7h to 3.0h Food effect (high fat meal/fasting): PK parameter ratio and 90% confidence interval a C max : 1.14 (0.95, 1.36) AUC: 1.30 (1.07, 1.51) a T max : ↔ Distribution % Bound to human plasma proteins (ex vivo) Unknown 1-2% over 0.5-51 mcg/mL Cerebrospinal fluid penetration Unknown Yes Metabolism Hydrolyzed by intestinal and liver esterases No significant metabolism Elimination Dose proportiona
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:390691b2-3db0-4b9f-934f-120674726f14 (opens source in a new tab)
Valganciclovir label
Version not recorded · Effective date not recorded
7h to 3.0h Food effect (high fat meal/fasting): PK parameter ratio and 90% confidence interval a C max : 1.14 (0.95, 1.36) AUC: 1.30 (1.07, 1.51) a T max : ↔ Distribution % Bound to human plasma proteins (ex vivo) Unknown 1-2% over 0.5-51 mcg/mL Cerebrospinal fluid penetration Unknown Yes Metabolism Hydrolyzed by intestinal and liver esterases No significant metabolism Elimination Dose proportiona
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cc6c4939-7908-439c-b1b8-6b52e826c7a5 (opens source in a new tab)
Valganciclovir label
Version not recorded · Effective date not recorded
h to 3.0h Food effect (high fat meal/fasting): PK parameter ratio and 90% confidence interval a C max : 1.14 (0.95, 1.36) AUC: 1.30 (1.07, 1.51) a T max : ↔ Distribution % Bound to human plasma proteins (ex vivo) Unknown 1 to 2% over 0.5 to 51 mcg/mL Cerebrospinal fluid penetration Unknown Yes Metabolism Hydrolyzed by intestinal and liver esterases No significant metabolism Elimination Dose propor
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f37c0780-b953-46c2-d7d4-959fc2c3e571 (opens source in a new tab)
Valganciclovir label
Version not recorded · Effective date not recorded
effect (high fat meal/fasting): PK parameter ratio and 90% confidence intervala Cmax: 1.14 (0.95, 1.36) AUC: 1.30 (1.07, 1.51)a Tmax: ↔ : 1.30 (1.07, 1.51)a Distribution % Bound to human plasma proteins (ex vivo) Unknown 1 to 2% over 0.5 to 51 mcg/mL Cerebrospinal fluid penetration Unknown Yes Metabolism Hydrolyzed by intestinal and liver esterases No significant metabolism Elimination Dose propor
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d2ffc05-2fbc-41f8-8656-fbc0bfa7ad83 (opens source in a new tab)
Valganciclovir label
Version not recorded · Effective date not recorded
to 3.0 h Food effect (high fat meal/fasting): PK parameter ratio and 90% confidence interval a C max : 1.14 (0.95, 1.36) AUC: 1.30 (1.07, 1.51) a T max : ↔ Distribution % Bound to human plasma proteins ( ex vivo ) Unknown 1 to 2% over 0.5 to 51 mcg/mL Cerebrospinal fluid penetration Unknown Yes Metabolism Hydrolyzed by intestinal and liver esterases No significant metabolism Elimination Dose propo
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4db6dd63-e56b-45a4-86b2-ee125a1854a0 (opens source in a new tab)
Valganciclovir label
Version not recorded · Effective date not recorded
C max : 1.14 (0.95, 1.36) AUC: 1.30 (1.07, 1.51) T max : ↔ Distribution % Bound to human plasma proteins (ex vivo) Unknown 1 to 2% over 0.5 to 51 mcg/mL Cerebrospinal fluid penetration Unknown Yes Metabolism Hydrolyzed by intestinal and liver esterases No significant metabolism Elimination Dose proportionality AUC was dose proportional under fed conditions across a valganciclovir dose range of 450
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:383e8810-b877-4a4f-abdf-c8c4c8e394f8 (opens source in a new tab)
Valganciclovir label
Version not recorded · Effective date not recorded
7h to 3.0h Food effect (high fat meal/fasting): PK parameter ratio and 90% confidence interval a C max : 1.14 (0.95, 1.36) AUC: 1.30 (1.07, 1.51) a T max : ↔ Distribution % Bound to human plasma proteins (ex vivo) Unknown 1–2% over 0.5– 51 mcg/mL Cerebrospinal fluid penetration Unknown Yes Metabolism Hydrolyzed by intestinal and liver esterases No significant metabolism Elimination Dose proportion
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:28703782-9f48-4866-a32d-1604da9dee6b (opens source in a new tab)
Valganciclovir label
Version not recorded · Effective date not recorded
to 3.0h Food effect (high fat meal/fasting): PK parameter ratio and 90% confidence interval a C max : 1.14 (0.95, 1.36) AUC: 1.30 (1.07, 1.51) a T max : ↔ Distribution % Bound to human plasma proteins ( ex vivo ) Unknown 1 to 2% over 0.5 to 51 mcg/mL Cerebrospinal fluid penetration Unknown Yes Metabolism Hydrolyzed by intestinal and liver esterases No significant metabolism Elimination Dose propo
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1cc09039-dcd6-4721-abd4-411535ccf442 (opens source in a new tab)
Valganciclovir label
Version not recorded · Effective date not recorded
to 3.0 h Food effect (high fat meal/fasting): PK parameter ratio and 90% confidence interval a C max : 1.14 (0.95, 1.36) AUC: 1.30 (1.07, 1.51) a T max : ↔ Distribution % Bound to human plasma proteins ( ex vivo ) Unknown 1 to 2% over 0.5 to 51 mcg/mL Cerebrospinal fluid penetration Unknown Yes Metabolism Hydrolyzed by intestinal and liver esterases No significant metabolism Elimination Dose propo
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c517a39-2ded-4c5a-8d56-276853414b31 (opens source in a new tab)
Valganciclovir label
Version not recorded · Effective date not recorded
C max : 1.14 (0.95, 1.36) AUC: 1.30 (1.07, 1.51) T max : ↔ Distribution % Bound to human plasma proteins (ex vivo) Unknown 1–2% over 0.5– 51 mcg/mL Cerebrospinal fluid penetration Unknown Yes Metabolism Hydrolyzed by intestinal and liver esterases No significant metabolism Elimination Dose proportionality AUC was dose proportional under fed conditions across a valganciclovir dose range of 450 to 2
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6a6533fd-0579-4059-ba87-aa399829a8b0 (opens source in a new tab)
Valganciclovir label
Version not recorded · Effective date not recorded
7h to 3.0h Food effect (high fat meal/fasting): PK parameter ratio and 90% confidence interval a C max : 1.14 (0.95, 1.36) AUC: 1.30 (1.07, 1.51) a T max : ↔ Distribution % Bound to human plasma proteins (ex vivo) Unknown 1–2% over 0.5– 51 mcg/mL Cerebrospinal fluid penetration Unknown Yes Metabolism Hydrolyzed by intestinal and liver esterases No significant metabolism Elimination Dose proportion
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e30ae2b2-dad2-39ba-6bc7-400807791ab0 (opens source in a new tab)
Valganciclovir label
Version not recorded · Effective date not recorded
(high fat meal/fasting): PK parameter ratio and 90% confidence interval a C max : 1.14 (0.95, 1.36) AUC: 1.30 (1.07, 1.51) a T max : ↔: 1.30 (1.07, 1.51) a Distribution % Bound to human plasma proteins ( ex vivo ) Unknown 1 to 2% over 0.5 to 51 mcg/mL Cerebrospinal fluid penetration Unknown Yes Metabolism Hydrolyzed by intestinal and liver esterases No significant metabolism Elimination Dose propo
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e30509f-add6-43c8-9e1d-e10c55a207e6 (opens source in a new tab)
Valganciclovir label
Version not recorded · Effective date not recorded
C max : 1.14 (0.95, 1.36)AUC: 1.30 (1.07, 1.51) T max : ↔ Distribution % Bound to human plasma proteins ( ex vivo ) Unknown 1 to 2% over 0.5 to 51 mcg/mL Cerebrospinal fluid penetration Unknown Yes Metabolism Hydrolyzed by intestinal and liver esterases No significant metabolism Elimination Dose proportionality AUC was dose proportional under fed conditions across a valganciclovir dose range of 45
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:39452b74-161d-4525-a0f7-fe486f001513 (opens source in a new tab)
Valganciclovir label
Version not recorded · Effective date not recorded
1.7h to 3h Food effect (high fat meal/fasting): PK parameter ratio and 90% confidence interval a C max : 1.14 (0.95, 1.36) AUC: 1.30 (1.07, 1.51) a Tmax: ↔ Distribution % Bound to human plasma proteins (ex vivo) Unknown 1 to 2% over 0.5 to 51 mcg/mL Cerebrospinal fluid penetration Unknown Yes Metabolism Hydrolyzed by intestinal and liver esterases No significant metabolism Elimination Dose propor
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ddfb4e0e-64f5-4654-8670-91b8b6abe794 (opens source in a new tab)
Valganciclovir label
Version not recorded · Effective date not recorded
C max : 1.14 (0.95, 1.36) AUC: 1.30 (1.07, 1.51) a T max : Distribution % Bound to human plasma proteins ( ex vivo ) Unknown 1 to 2% over 0.5 to 51 mcg/mL Cerebrospinal fluid penetration Unknown Yes Metabolism Hydrolyzed by intestinal and liver esterases No significant metabolism Elimination Dose proportionality AUC was dose proportional under fed conditions across a valganciclovir dose range of 4
1%
- Numeric value
- 1
- Unit
- %
- Source records
- 6
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 6 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92281301-5fb5-4eea-8766-4863e241c234 (opens source in a new tab)
Valganciclovir label
Version not recorded · Effective date not recorded
.7h to 3.0h Food effect (high fat meal/fasting): PK parameter ratio and 90% confidence interval a C max : 1.14 (0.95, 1.36) AUC: 1.30 (1.07, 1.51) a T max : ↔ Distribution % Bound to human plasma proteins (ex vivo) Unknown 1% to 2% over 0.5 mcg/mL to 51 mcg/mL Cerebrospinal fluid penetration Unknown Yes Metabolism Hydrolyzed by intestinal and liver esterases No significant metabolism Elimination
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:85177859-e0f5-6d83-17f3-29cae1db96c3 (opens source in a new tab)
Valganciclovir label
Version not recorded · Effective date not recorded
Plasma protein binding of ganciclovir is 1% to 2% over concentrations of 0.5 and 51 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:facbcc41-52cf-4433-b3fc-9bf8f06dcdd9 (opens source in a new tab)
Valganciclovir label
Version not recorded · Effective date not recorded
.7h to 3.0h Food effect (high fat meal/fasting): PK parameter ratio and 90% confidence interval a C max : 1.14 (0.95, 1.36) AUC: 1.30 (1.07, 1.51) a T max : ↔ Distribution % Bound to human plasma proteins (ex vivo) Unknown 1% to 2% over 0.5 to 51 mcg/mL Cerebrospinal fluid penetration Unknown Yes Metabolism Hydrolyzed by intestinal and liver esterases No significant metabolism Elimination Dose pro
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:178a014b-92c7-44a7-abb8-95d89a2feb8f (opens source in a new tab)
Valganciclovir label
Version not recorded · Effective date not recorded
.7h to 3.0h Food effect (high fat meal/fasting): PK parameter ratio and 90% confidence interval a C max : 1.14 (0.95, 1.36) AUC: 1.30 (1.07, 1.51) a T max : ↔ Distribution % Bound to human plasma proteins (ex vivo) Unknown 1% to 2% over 0.5 mcg/mL to 51 mcg/mL Cerebrospinal fluid penetration Unknown Yes Metabolism Hydrolyzed by intestinal and liver esterases No significant metabolism Elimination D
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d13cc8ad-eaf0-4ae6-89da-a850a08b1067 (opens source in a new tab)
Valganciclovir label
Version not recorded · Effective date not recorded
h to 3.0 h Food effect (high fat meal/fasting): PK parameter ratio and 90% confidence interval a C max : 1.14 (0.95, 1.36) AUC: 1.30 (1.07, 1.51) a T max : ↔ Distribution % Bound to human plasma proteins (ex vivo) Unknown 1% to 2% over 0.5 mcg/mL to 51 mcg/mL Cerebrospinal fluid penetration Unknown Yes Metabolism Hydrolyzed by intestinal and liver esterases No significant metabolism Elimination D
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:07eb5abf-2322-4fb9-e063-6394a90a2311 (opens source in a new tab)
Valganciclovir label
Version not recorded · Effective date not recorded
.7h to 3.0h Food effect (high fat meal/fasting): PK parameter ratio and 90% confidence interval a C max : 1.14 (0.95, 1.36) AUC: 1.30 (1.07, 1.51) a T max : ↔ Distribution % Bound to human plasma proteins (ex vivo) Unknown 1% to 2% over 0.5 mcg/mL to 51 mcg/mL Cerebrospinal fluid penetration Unknown Yes Metabolism Hydrolyzed by intestinal and liver esterases No significant metabolism Elimination
2%
- Numeric value
- 2
- Unit
- %
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b856bfaf-ec6b-4171-81c4-b9b07f780084 (opens source in a new tab)
Valganciclovir label
Version not recorded · Effective date not recorded
1.7h to 3h Food effect (high fat meal/fasting): PK parameter ratio and 90% confidence intervala C max : 1.14 (0.95, 1.36) AUC: 1.30 (1.07, 1.51)a T max : ↔ Distribution % Bound to human plasma proteins (ex vivo) Unknown 1 to 2% over 0.5 to 51 mcg/mL Cerebrospinal fluid penetration Unknown Yes Metabolism Hydrolyzed by intestinal and liver esterases No significant metabolism Elimination Dose propo
Projected row 1602
- Medicine slug
- valproate
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 5
- Source count
- 5
- Agreement rate
- 1
- Recorded readings
10 to 67 hours
- Numeric value
- 10
- Unit
- hours
- Source records
- 5
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 5 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3dfb6da1-f66a-4618-9f74-d2d6c16c0b58 (opens source in a new tab)
Valproate label
Version not recorded · Effective date not recorded
For example, in one study, the half-life in children under 10 days ranged from 10 to 67 hours compared to a range of 7 to 13 hours in children greater than 2 months.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bcf57b31-4811-4104-82b3-46fb91a53ee0 (opens source in a new tab)
Valproate label
Version not recorded · Effective date not recorded
For example, in one study, the half-life in children under 10 days ranged from 10 to 67 hours compared to a range of 7 to 13 hours in children greater than 2 months.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7a687b2f-246d-4736-a20c-92421c263268 (opens source in a new tab)
Valproate label
Version not recorded · Effective date not recorded
For example, in one study, the half-life in children under 10 days ranged from 10 to 67 hours compared to a range of 7 to 13 hours in children greater than 2 months.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c572ece7-03d3-4c2a-aeb5-61f2023b28ea (opens source in a new tab)
Valproate label
Version not recorded · Effective date not recorded
For example, in one study, the half-life in children under 10 days ranged from 10 to 67 hours compared to a range of 7 to 13 hours in children greater than 2 months.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d5fc1c1-d3c0-497e-971b-6c4dba9a3fad (opens source in a new tab)
Valproate label
Version not recorded · Effective date not recorded
For example, in one study, the half-life in children under 10 days ranged from 10 to 67 hours compared to a range of 7 to 13 hours in children greater than 2 months.
Projected row 1603
- Medicine slug
- valproate
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 5
- Source count
- 5
- Agreement rate
- 1
- Recorded readings
4 hours
- Numeric value
- 4
- Unit
- hours
- Source records
- 5
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 5 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3dfb6da1-f66a-4618-9f74-d2d6c16c0b58 (opens source in a new tab)
Valproate label
Version not recorded · Effective date not recorded
The T max after IV valproate sodium occurs at the end of the one hour infusion, while the T max after oral dosing with divalproex sodium occurs at approximately 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bcf57b31-4811-4104-82b3-46fb91a53ee0 (opens source in a new tab)
Valproate label
Version not recorded · Effective date not recorded
The T max after IV Valproate Sodium Injection occurs at the end of the one hour infusion, while the T max after oral dosing with divalproex sodium occurs at approximately 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7a687b2f-246d-4736-a20c-92421c263268 (opens source in a new tab)
Valproate label
Version not recorded · Effective date not recorded
The T max after IV Valproate Sodium Injection occurs at the end of the one hour infusion, while the T max after oral dosing with divalproex sodium occurs at approximately 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c572ece7-03d3-4c2a-aeb5-61f2023b28ea (opens source in a new tab)
Valproate label
Version not recorded · Effective date not recorded
The T max after IV valproate sodium occurs at the end of the one hour infusion, while the T max after oral dosing with divalproex sodium occurs at approximately 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d5fc1c1-d3c0-497e-971b-6c4dba9a3fad (opens source in a new tab)
Valproate label
Version not recorded · Effective date not recorded
The T max after IV Valproate Sodium Injection occurs at the end of the one hour infusion, while the T max after oral dosing with divalproex sodium occurs at approximately 4 hours.
Projected row 1604
- Medicine slug
- valproate
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 5
- Source count
- 5
- Agreement rate
- 1
- Recorded readings
0.56 L
- Numeric value
- 0.56
- Unit
- L
- Source records
- 5
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 5 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3dfb6da1-f66a-4618-9f74-d2d6c16c0b58 (opens source in a new tab)
Valproate label
Version not recorded · Effective date not recorded
Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bcf57b31-4811-4104-82b3-46fb91a53ee0 (opens source in a new tab)
Valproate label
Version not recorded · Effective date not recorded
Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7a687b2f-246d-4736-a20c-92421c263268 (opens source in a new tab)
Valproate label
Version not recorded · Effective date not recorded
Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c572ece7-03d3-4c2a-aeb5-61f2023b28ea (opens source in a new tab)
Valproate label
Version not recorded · Effective date not recorded
Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d5fc1c1-d3c0-497e-971b-6c4dba9a3fad (opens source in a new tab)
Valproate label
Version not recorded · Effective date not recorded
Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
Projected row 1605
- Medicine slug
- valproic-acid
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 24
- Source count
- 23
- Agreement rate
- 1
- Recorded readings
9 to 16 hours
- Numeric value
- 9
- Unit
- hours
- Source records
- 23
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 23 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8bdbacb1-b38a-3282-e053-2a95a90af022 (opens source in a new tab)
Valproic Acid label
Version not recorded · Effective date not recorded
Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3a2155d0-e79d-3e11-e063-6294a90a4aae (opens source in a new tab)
Valproic Acid label
Version not recorded · Effective date not recorded
Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cef3e335-5891-412f-89c4-79fcd2f145b7 (opens source in a new tab)
Valproic Acid label
Version not recorded · Effective date not recorded
Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1000 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1286ab49-fa34-488e-e063-6394a90ad582 (opens source in a new tab)
Valproic Acid label
Version not recorded · Effective date not recorded
Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7d5cb52e-37dd-4dfa-a6f4-09f9548846c6 (opens source in a new tab)
Valproic Acid label
Version not recorded · Effective date not recorded
Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ceb52870-76d0-4108-a1d4-ba7096fbacdd (opens source in a new tab)
Valproic Acid label
Version not recorded · Effective date not recorded
Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a33f7657-ad0f-43e9-ba48-024746e6d08e (opens source in a new tab)
Valproic Acid label
Version not recorded · Effective date not recorded
Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8051ad62-3b6e-461e-8090-60f5c0a904f4 (opens source in a new tab)
Valproic Acid label
Version not recorded · Effective date not recorded
Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8785a152-3010-4370-aaf5-11315a1a56e1 (opens source in a new tab)
Valproic Acid label
Version not recorded · Effective date not recorded
Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a9cef1ec-ba52-4849-8889-87898d6f4199 (opens source in a new tab)
Valproic Acid label
Version not recorded · Effective date not recorded
Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db53c5aa-d7a5-49ba-8227-c2d67ced23e2 (opens source in a new tab)
Valproic Acid label
Version not recorded · Effective date not recorded
Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:65c1589e-c591-4b79-b75e-884c0d609ae8 (opens source in a new tab)
Valproic Acid label
Version not recorded · Effective date not recorded
Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ec41025a-ed7d-48c8-9005-08e3a9417f30 (opens source in a new tab)
Valproic Acid label
Version not recorded · Effective date not recorded
Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2314af65-b928-42a9-91eb-6372909ab4f5 (opens source in a new tab)
Valproic Acid label
Version not recorded · Effective date not recorded
Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:531c0fc7-5e80-49a5-a9d1-0916ec45d52c (opens source in a new tab)
Valproic Acid label
Version not recorded · Effective date not recorded
Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:453444b6-1f50-49de-ab3c-1e429c83bffa (opens source in a new tab)
Valproic Acid label
Version not recorded · Effective date not recorded
Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1edd220d-d151-4177-9a29-9fee36489fb7 (opens source in a new tab)
Valproic Acid label
Version not recorded · Effective date not recorded
Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7d4df6ad-3d53-4664-9200-749487bf3689 (opens source in a new tab)
Valproic Acid label
Version not recorded · Effective date not recorded
Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3904177b-8a26-4356-9080-d2a2e3f468af (opens source in a new tab)
Valproic Acid label
Version not recorded · Effective date not recorded
Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1000 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:34a0d45a-4388-7d8b-e063-6394a90a6c3f (opens source in a new tab)
Valproic Acid label
Version not recorded · Effective date not recorded
Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1000 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5d19f389-7180-4e01-845f-519b7ea60ba0 (opens source in a new tab)
Valproic Acid label
Version not recorded · Effective date not recorded
Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4b619f73-44e5-4a99-b425-a96cb2228c87 (opens source in a new tab)
Valproic Acid label
Version not recorded · Effective date not recorded
Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3798f957-8b32-4ac0-8fd1-80283414c255 (opens source in a new tab)
Valproic Acid label
Version not recorded · Effective date not recorded
Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1000 mg.
Projected row 1606
- Medicine slug
- valproic-acid
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 24
- Source count
- 23
- Agreement rate
- 1
- Recorded readings
0.56 L
- Numeric value
- 0.56
- Unit
- L
- Source records
- 23
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 23 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8bdbacb1-b38a-3282-e053-2a95a90af022 (opens source in a new tab)
Valproic Acid label
Version not recorded · Effective date not recorded
Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m2 and 11 L/1.73 m2, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3a2155d0-e79d-3e11-e063-6294a90a4aae (opens source in a new tab)
Valproic Acid label
Version not recorded · Effective date not recorded
Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cef3e335-5891-412f-89c4-79fcd2f145b7 (opens source in a new tab)
Valproic Acid label
Version not recorded · Effective date not recorded
Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1286ab49-fa34-488e-e063-6394a90ad582 (opens source in a new tab)
Valproic Acid label
Version not recorded · Effective date not recorded
Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7d5cb52e-37dd-4dfa-a6f4-09f9548846c6 (opens source in a new tab)
Valproic Acid label
Version not recorded · Effective date not recorded
Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ceb52870-76d0-4108-a1d4-ba7096fbacdd (opens source in a new tab)
Valproic Acid label
Version not recorded · Effective date not recorded
Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a33f7657-ad0f-43e9-ba48-024746e6d08e (opens source in a new tab)
Valproic Acid label
Version not recorded · Effective date not recorded
Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8051ad62-3b6e-461e-8090-60f5c0a904f4 (opens source in a new tab)
Valproic Acid label
Version not recorded · Effective date not recorded
Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8785a152-3010-4370-aaf5-11315a1a56e1 (opens source in a new tab)
Valproic Acid label
Version not recorded · Effective date not recorded
Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a9cef1ec-ba52-4849-8889-87898d6f4199 (opens source in a new tab)
Valproic Acid label
Version not recorded · Effective date not recorded
Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db53c5aa-d7a5-49ba-8227-c2d67ced23e2 (opens source in a new tab)
Valproic Acid label
Version not recorded · Effective date not recorded
Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:65c1589e-c591-4b79-b75e-884c0d609ae8 (opens source in a new tab)
Valproic Acid label
Version not recorded · Effective date not recorded
Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ec41025a-ed7d-48c8-9005-08e3a9417f30 (opens source in a new tab)
Valproic Acid label
Version not recorded · Effective date not recorded
Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2314af65-b928-42a9-91eb-6372909ab4f5 (opens source in a new tab)
Valproic Acid label
Version not recorded · Effective date not recorded
Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:531c0fc7-5e80-49a5-a9d1-0916ec45d52c (opens source in a new tab)
Valproic Acid label
Version not recorded · Effective date not recorded
Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:453444b6-1f50-49de-ab3c-1e429c83bffa (opens source in a new tab)
Valproic Acid label
Version not recorded · Effective date not recorded
Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1edd220d-d151-4177-9a29-9fee36489fb7 (opens source in a new tab)
Valproic Acid label
Version not recorded · Effective date not recorded
Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7d4df6ad-3d53-4664-9200-749487bf3689 (opens source in a new tab)
Valproic Acid label
Version not recorded · Effective date not recorded
Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3904177b-8a26-4356-9080-d2a2e3f468af (opens source in a new tab)
Valproic Acid label
Version not recorded · Effective date not recorded
Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:34a0d45a-4388-7d8b-e063-6394a90a6c3f (opens source in a new tab)
Valproic Acid label
Version not recorded · Effective date not recorded
Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5d19f389-7180-4e01-845f-519b7ea60ba0 (opens source in a new tab)
Valproic Acid label
Version not recorded · Effective date not recorded
Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4b619f73-44e5-4a99-b425-a96cb2228c87 (opens source in a new tab)
Valproic Acid label
Version not recorded · Effective date not recorded
Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3798f957-8b32-4ac0-8fd1-80283414c255 (opens source in a new tab)
Valproic Acid label
Version not recorded · Effective date not recorded
Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
Projected row 1607
- Medicine slug
- valsartan
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 63
- Source count
- 60
- Agreement rate
- 1
- Recorded readings
25%
- Numeric value
- 25
- Unit
- %
- Source records
- 60
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 60 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9402b022-5809-4251-dfef-54f6ef5723fe (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5ddba454-f3e6-43c2-a7a6-58365d297213 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for Diovan is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a8c61488-4219-dfcb-e053-2a95a90a98a4 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6e1f63ad-e554-421b-a699-4e8c9bd4d239 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:75235313-8a07-8849-9b5a-12887992033e (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a81a72dd-e828-4208-af9b-bb9ac4938537 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e8fcd4c2-8baa-452a-b723-5cb3d8d203a9 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b58471fe-e2c6-4cc5-9d49-6a3111f6e002 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2b77f2f-333e-f3e3-e053-2a95a90a1fa7 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan tablets is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b3880f58-ce15-4701-84aa-8eb185cf43e2 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3eee9505-ebba-76e3-e063-6294a90acd6e (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59d3db05-2d63-9dbf-e063-6394a90a8dd3 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f4a5df78-157b-4996-845c-235234250f11 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7b523502-62b3-425e-960b-f0a58919d3ec (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8478a05f-38fd-412d-af49-69a73a787c8f (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5ee97546-2a7c-40fa-9e05-b7993a72dfbf (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for Valsartan is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:03af7d09-314a-fe85-e063-6294a90afa25 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:93b82a9f-dc0a-4f7d-b0d4-4adf0d917b7e (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:26080940-bcd3-446d-9026-3ddfb58e281e (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0878f27e-5368-c93f-e063-6394a90a1086 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6e9c4c57-e2c9-461b-9c09-669d3ada4c1a (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7aaa0a16-d7c6-4952-aa27-0b4b8982dc5f (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan tablet is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9eb9d98e-7057-4ca0-91ab-2030bc0120a6 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan tablets is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f5a400f-9cfc-4d25-a677-73cbb14375e2 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7b4ecaf9-e84c-4660-9cd1-65a238efd8a8 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan tablet is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c12db287-786c-47ae-a1f3-df04ddfd2a70 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:251ccff4-bf86-453b-9d1c-e3c1ecfd3a46 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan tablets is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:73e01dc6-7dd4-421a-a4f6-137e75f69f9a (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan tablets is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f59f71d3-c143-43e5-ac22-0b1d741f4a81 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f13587f8-76cb-49ad-9291-5907249d6b8e (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fadb25bb-acd9-4aaf-971c-82259b739e5b (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan tablets is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9a16816-d4de-401a-8413-7233f4e541f8 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2847db2a-fcc9-4776-875a-ba6d57d5ea8b (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f756009f-f04f-6518-e053-6294a90a79ed (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4d6e85d8-7d51-4447-b43d-c2a77f4fe3ae (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7cb9f284-8175-4679-b846-145dc604e2c0 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan tablets is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9af6ba1-c760-4af6-b733-88e4892d4cb6 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bd7b35c7-9f01-4afd-b497-bbe0f3d69b29 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:506ab3dd-c5eb-4755-ad10-bc116f4443c7 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e352db8b-0485-492a-8734-0a415566d764 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bcbd44f6-d49a-4a59-bba5-70fb843d1f59 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:80987771-ccb4-4a9f-a395-0af4c2621e0a (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:946692f5-0fe2-89b7-e053-2995a90a4d91 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan tablets is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3dfe5407-96a6-d2f4-e063-6294a90aa810 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f305e9d7-341a-45f6-e053-2a95a90a2d69 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan tablets is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d6e84105-9394-4ef0-928c-20d07d3fbaa9 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:04b3c573-4ef7-5cf6-e063-6294a90a2c5f (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan tablet is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ab5e0e5a-5bdf-4cfc-9d18-57ea4d642f65 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan tablets is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7ea2fdf1-4fda-47a7-8110-62fb6468c989 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan tablet is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:170427e5-c74c-c7fc-e063-6294a90a6860 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan tablet is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5afd7c3d-c66b-479c-bfd0-6c04658b157d (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0925a24f-6a72-4c77-b4e6-0a8f5b12c8d0 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:04b3301f-e054-ed5d-e063-6294a90a819c (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a8af3d9-4053-4233-82a7-e8c7bc9e302f (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:688b5c82-2eba-445c-869e-60609f5db86a (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4e160647-a08e-40e8-b566-3e97a09c616a (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0ff36e83-b307-42db-a2ab-bae3f6805c20 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db4801e5-6e0f-2cb3-e053-2995a90a709a (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bb3c66a7-d397-4df5-822f-4a1f797f54fc (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan tablets is about 25% (range 10% to 35%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6e2cd953-88bf-4094-8ba8-2c9ba020f4d7 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Absolute bioavailability for valsartan is about 25% (range 10% to 35%).
Projected row 1608
- Medicine slug
- valsartan
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 63
- Source count
- 63
- Agreement rate
- 1
- Recorded readings
6 hours
- Numeric value
- 6
- Unit
- hours
- Source records
- 63
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 63 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9402b022-5809-4251-dfef-54f6ef5723fe (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5ddba454-f3e6-43c2-a7a6-58365d297213 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a8c61488-4219-dfcb-e053-2a95a90a98a4 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6e1f63ad-e554-421b-a699-4e8c9bd4d239 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:75235313-8a07-8849-9b5a-12887992033e (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a81a72dd-e828-4208-af9b-bb9ac4938537 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e8fcd4c2-8baa-452a-b723-5cb3d8d203a9 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b58471fe-e2c6-4cc5-9d49-6a3111f6e002 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2b77f2f-333e-f3e3-e053-2a95a90a1fa7 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b3880f58-ce15-4701-84aa-8eb185cf43e2 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3eee9505-ebba-76e3-e063-6294a90acd6e (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59d3db05-2d63-9dbf-e063-6394a90a8dd3 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f4a5df78-157b-4996-845c-235234250f11 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7b523502-62b3-425e-960b-f0a58919d3ec (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8478a05f-38fd-412d-af49-69a73a787c8f (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5ee97546-2a7c-40fa-9e05-b7993a72dfbf (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:03af7d09-314a-fe85-e063-6294a90afa25 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:93b82a9f-dc0a-4f7d-b0d4-4adf0d917b7e (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:26080940-bcd3-446d-9026-3ddfb58e281e (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0878f27e-5368-c93f-e063-6394a90a1086 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47137b1a-f2b0-49af-99f0-6fb4f5a16578 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6e9c4c57-e2c9-461b-9c09-669d3ada4c1a (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7aaa0a16-d7c6-4952-aa27-0b4b8982dc5f (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9eb9d98e-7057-4ca0-91ab-2030bc0120a6 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f5a400f-9cfc-4d25-a677-73cbb14375e2 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:959b6790-feb7-45a9-9ea4-0ee1a7fce048 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7b4ecaf9-e84c-4660-9cd1-65a238efd8a8 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c12db287-786c-47ae-a1f3-df04ddfd2a70 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:251ccff4-bf86-453b-9d1c-e3c1ecfd3a46 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:73e01dc6-7dd4-421a-a4f6-137e75f69f9a (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f59f71d3-c143-43e5-ac22-0b1d741f4a81 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f13587f8-76cb-49ad-9291-5907249d6b8e (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fadb25bb-acd9-4aaf-971c-82259b739e5b (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9a16816-d4de-401a-8413-7233f4e541f8 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2847db2a-fcc9-4776-875a-ba6d57d5ea8b (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f756009f-f04f-6518-e053-6294a90a79ed (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4d6e85d8-7d51-4447-b43d-c2a77f4fe3ae (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7cb9f284-8175-4679-b846-145dc604e2c0 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9af6ba1-c760-4af6-b733-88e4892d4cb6 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bd7b35c7-9f01-4afd-b497-bbe0f3d69b29 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:130e1659-9c2d-49ca-9db8-d28aa23fd133 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:506ab3dd-c5eb-4755-ad10-bc116f4443c7 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e352db8b-0485-492a-8734-0a415566d764 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bcbd44f6-d49a-4a59-bba5-70fb843d1f59 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:80987771-ccb4-4a9f-a395-0af4c2621e0a (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:946692f5-0fe2-89b7-e053-2995a90a4d91 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3dfe5407-96a6-d2f4-e063-6294a90aa810 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f305e9d7-341a-45f6-e053-2a95a90a2d69 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d6e84105-9394-4ef0-928c-20d07d3fbaa9 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:04b3c573-4ef7-5cf6-e063-6294a90a2c5f (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ab5e0e5a-5bdf-4cfc-9d18-57ea4d642f65 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7ea2fdf1-4fda-47a7-8110-62fb6468c989 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:170427e5-c74c-c7fc-e063-6294a90a6860 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5afd7c3d-c66b-479c-bfd0-6c04658b157d (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0925a24f-6a72-4c77-b4e6-0a8f5b12c8d0 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:04b3301f-e054-ed5d-e063-6294a90a819c (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a8af3d9-4053-4233-82a7-e8c7bc9e302f (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:688b5c82-2eba-445c-869e-60609f5db86a (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4e160647-a08e-40e8-b566-3e97a09c616a (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0ff36e83-b307-42db-a2ab-bae3f6805c20 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db4801e5-6e0f-2cb3-e053-2995a90a709a (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bb3c66a7-d397-4df5-822f-4a1f797f54fc (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6e2cd953-88bf-4094-8ba8-2c9ba020f4d7 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
Projected row 1609
- Medicine slug
- valsartan
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 63
- Source count
- 63
- Agreement rate
- 1
- Recorded readings
95%
- Numeric value
- 95
- Unit
- %
- Source records
- 63
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 63 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9402b022-5809-4251-dfef-54f6ef5723fe (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5ddba454-f3e6-43c2-a7a6-58365d297213 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a8c61488-4219-dfcb-e053-2a95a90a98a4 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6e1f63ad-e554-421b-a699-4e8c9bd4d239 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:75235313-8a07-8849-9b5a-12887992033e (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a81a72dd-e828-4208-af9b-bb9ac4938537 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e8fcd4c2-8baa-452a-b723-5cb3d8d203a9 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b58471fe-e2c6-4cc5-9d49-6a3111f6e002 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2b77f2f-333e-f3e3-e053-2a95a90a1fa7 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b3880f58-ce15-4701-84aa-8eb185cf43e2 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3eee9505-ebba-76e3-e063-6294a90acd6e (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59d3db05-2d63-9dbf-e063-6394a90a8dd3 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f4a5df78-157b-4996-845c-235234250f11 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7b523502-62b3-425e-960b-f0a58919d3ec (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8478a05f-38fd-412d-af49-69a73a787c8f (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5ee97546-2a7c-40fa-9e05-b7993a72dfbf (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:03af7d09-314a-fe85-e063-6294a90afa25 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:93b82a9f-dc0a-4f7d-b0d4-4adf0d917b7e (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:26080940-bcd3-446d-9026-3ddfb58e281e (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0878f27e-5368-c93f-e063-6394a90a1086 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47137b1a-f2b0-49af-99f0-6fb4f5a16578 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6e9c4c57-e2c9-461b-9c09-669d3ada4c1a (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7aaa0a16-d7c6-4952-aa27-0b4b8982dc5f (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9eb9d98e-7057-4ca0-91ab-2030bc0120a6 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f5a400f-9cfc-4d25-a677-73cbb14375e2 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:959b6790-feb7-45a9-9ea4-0ee1a7fce048 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7b4ecaf9-e84c-4660-9cd1-65a238efd8a8 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c12db287-786c-47ae-a1f3-df04ddfd2a70 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:251ccff4-bf86-453b-9d1c-e3c1ecfd3a46 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:73e01dc6-7dd4-421a-a4f6-137e75f69f9a (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f59f71d3-c143-43e5-ac22-0b1d741f4a81 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f13587f8-76cb-49ad-9291-5907249d6b8e (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fadb25bb-acd9-4aaf-971c-82259b739e5b (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9a16816-d4de-401a-8413-7233f4e541f8 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2847db2a-fcc9-4776-875a-ba6d57d5ea8b (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f756009f-f04f-6518-e053-6294a90a79ed (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4d6e85d8-7d51-4447-b43d-c2a77f4fe3ae (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7cb9f284-8175-4679-b846-145dc604e2c0 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9af6ba1-c760-4af6-b733-88e4892d4cb6 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bd7b35c7-9f01-4afd-b497-bbe0f3d69b29 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:130e1659-9c2d-49ca-9db8-d28aa23fd133 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:506ab3dd-c5eb-4755-ad10-bc116f4443c7 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e352db8b-0485-492a-8734-0a415566d764 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bcbd44f6-d49a-4a59-bba5-70fb843d1f59 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:80987771-ccb4-4a9f-a395-0af4c2621e0a (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:946692f5-0fe2-89b7-e053-2995a90a4d91 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3dfe5407-96a6-d2f4-e063-6294a90aa810 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f305e9d7-341a-45f6-e053-2a95a90a2d69 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d6e84105-9394-4ef0-928c-20d07d3fbaa9 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:04b3c573-4ef7-5cf6-e063-6294a90a2c5f (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ab5e0e5a-5bdf-4cfc-9d18-57ea4d642f65 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7ea2fdf1-4fda-47a7-8110-62fb6468c989 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:170427e5-c74c-c7fc-e063-6294a90a6860 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5afd7c3d-c66b-479c-bfd0-6c04658b157d (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0925a24f-6a72-4c77-b4e6-0a8f5b12c8d0 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:04b3301f-e054-ed5d-e063-6294a90a819c (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a8af3d9-4053-4233-82a7-e8c7bc9e302f (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:688b5c82-2eba-445c-869e-60609f5db86a (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4e160647-a08e-40e8-b566-3e97a09c616a (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0ff36e83-b307-42db-a2ab-bae3f6805c20 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db4801e5-6e0f-2cb3-e053-2995a90a709a (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bb3c66a7-d397-4df5-822f-4a1f797f54fc (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6e2cd953-88bf-4094-8ba8-2c9ba020f4d7 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
Valsartan is highly bound to serum proteins (95%), mainly serum albumin.
Projected row 1610
- Medicine slug
- valsartan
- Compared field
- tMax
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 63
- Source count
- 60
- Agreement rate
- 0.966667
- Recorded readings
2 to 4 hours
- Numeric value
- 2
- Unit
- hours
- Source records
- 58
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 58 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9402b022-5809-4251-dfef-54f6ef5723fe (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5ddba454-f3e6-43c2-a7a6-58365d297213 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a8c61488-4219-dfcb-e053-2a95a90a98a4 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
In multiple-dose studies in hypertensive patients, valsartan had no notable effects on total cholesterol, fasting triglycerides, fasting serum glucose, or uric acid. 12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6e1f63ad-e554-421b-a699-4e8c9bd4d239 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:75235313-8a07-8849-9b5a-12887992033e (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a81a72dd-e828-4208-af9b-bb9ac4938537 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e8fcd4c2-8baa-452a-b723-5cb3d8d203a9 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
In multiple-dose studies in hypertensive patients, valsartan had no notable effects on total cholesterol, fasting triglycerides, fasting serum glucose, or uric acid. 12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b58471fe-e2c6-4cc5-9d49-6a3111f6e002 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
In multiple-dose studies in hypertensive patients, valsartan had no notable effects on total cholesterol, fasting triglycerides, fasting serum glucose, or uric acid. 12.3 Pharmacokinetics Valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2b77f2f-333e-f3e3-e053-2a95a90a1fa7 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b3880f58-ce15-4701-84aa-8eb185cf43e2 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3eee9505-ebba-76e3-e063-6294a90acd6e (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59d3db05-2d63-9dbf-e063-6394a90a8dd3 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
In multiple-dose studies in hypertensive patients, valsartan had no notable effects on total cholesterol, fasting triglycerides, fasting serum glucose, or uric acid. 12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f4a5df78-157b-4996-845c-235234250f11 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
In multiple-dose studies in hypertensive patients, valsartan had no notable effects on total cholesterol, fasting triglycerides, fasting serum glucose, or uric acid. 12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7b523502-62b3-425e-960b-f0a58919d3ec (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8478a05f-38fd-412d-af49-69a73a787c8f (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5ee97546-2a7c-40fa-9e05-b7993a72dfbf (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:03af7d09-314a-fe85-e063-6294a90afa25 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
In multiple-dose studies in hypertensive patients, valsartan had no notable effects on total cholesterol, fasting triglycerides, fasting serum glucose, or uric acid. 12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:93b82a9f-dc0a-4f7d-b0d4-4adf0d917b7e (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:26080940-bcd3-446d-9026-3ddfb58e281e (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
In multiple-dose studies in hypertensive patients, valsartan had no notable effects on total cholesterol, fasting triglycerides, fasting serum glucose, or uric acid. 12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0878f27e-5368-c93f-e063-6394a90a1086 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6e9c4c57-e2c9-461b-9c09-669d3ada4c1a (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7aaa0a16-d7c6-4952-aa27-0b4b8982dc5f (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9eb9d98e-7057-4ca0-91ab-2030bc0120a6 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f5a400f-9cfc-4d25-a677-73cbb14375e2 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7b4ecaf9-e84c-4660-9cd1-65a238efd8a8 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c12db287-786c-47ae-a1f3-df04ddfd2a70 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:251ccff4-bf86-453b-9d1c-e3c1ecfd3a46 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:73e01dc6-7dd4-421a-a4f6-137e75f69f9a (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f59f71d3-c143-43e5-ac22-0b1d741f4a81 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f13587f8-76cb-49ad-9291-5907249d6b8e (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
In multiple-dose studies in hypertensive patients, valsartan had no notable effects on total cholesterol, fasting triglycerides, fasting serum glucose, or uric acid. 12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fadb25bb-acd9-4aaf-971c-82259b739e5b (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9a16816-d4de-401a-8413-7233f4e541f8 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
In multiple-dose studies in hypertensive patients, valsartan had no notable effects on total cholesterol, fasting triglycerides, fasting serum glucose, or uric acid. 12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2847db2a-fcc9-4776-875a-ba6d57d5ea8b (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
In multiple-dose studies in hypertensive patients, valsartan had no notable effects on total cholesterol, fasting triglycerides, fasting serum glucose, or uric acid. 12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f756009f-f04f-6518-e053-6294a90a79ed (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7cb9f284-8175-4679-b846-145dc604e2c0 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9af6ba1-c760-4af6-b733-88e4892d4cb6 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
In multiple-dose studies in hypertensive patients, valsartan had no notable effects on total cholesterol, fasting triglycerides, fasting serum glucose, or uric acid. 12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:506ab3dd-c5eb-4755-ad10-bc116f4443c7 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e352db8b-0485-492a-8734-0a415566d764 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bcbd44f6-d49a-4a59-bba5-70fb843d1f59 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
In multiple-dose studies in hypertensive patients, valsartan had no notable effects on total cholesterol, fasting triglycerides, fasting serum glucose, or uric acid. 12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:80987771-ccb4-4a9f-a395-0af4c2621e0a (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:946692f5-0fe2-89b7-e053-2995a90a4d91 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
In multiple-dose studies in hypertensive patients, valsartan had no notable effects on total cholesterol, fasting triglycerides, fasting serum glucose, or uric acid. 12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3dfe5407-96a6-d2f4-e063-6294a90aa810 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f305e9d7-341a-45f6-e053-2a95a90a2d69 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d6e84105-9394-4ef0-928c-20d07d3fbaa9 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:04b3c573-4ef7-5cf6-e063-6294a90a2c5f (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ab5e0e5a-5bdf-4cfc-9d18-57ea4d642f65 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7ea2fdf1-4fda-47a7-8110-62fb6468c989 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:170427e5-c74c-c7fc-e063-6294a90a6860 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
In multiple-dose studies in hypertensive patients, valsartan had no notable effects on total cholesterol, fasting triglycerides, fasting serum glucose, or uric acid. 12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5afd7c3d-c66b-479c-bfd0-6c04658b157d (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0925a24f-6a72-4c77-b4e6-0a8f5b12c8d0 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:04b3301f-e054-ed5d-e063-6294a90a819c (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a8af3d9-4053-4233-82a7-e8c7bc9e302f (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
In multiple-dose studies in hypertensive patients, valsartan had no notable effects on total cholesterol, fasting triglycerides, fasting serum glucose, or uric acid. 12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:688b5c82-2eba-445c-869e-60609f5db86a (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4e160647-a08e-40e8-b566-3e97a09c616a (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
In multiple-dose studies in hypertensive patients, valsartan had no notable effects on total cholesterol, fasting triglycerides, fasting serum glucose, or uric acid. 12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0ff36e83-b307-42db-a2ab-bae3f6805c20 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db4801e5-6e0f-2cb3-e053-2995a90a709a (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bb3c66a7-d397-4df5-822f-4a1f797f54fc (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6e2cd953-88bf-4094-8ba8-2c9ba020f4d7 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
2 hours
- Numeric value
- 2
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4d6e85d8-7d51-4447-b43d-c2a77f4fe3ae (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 hours to 4 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bd7b35c7-9f01-4afd-b497-bbe0f3d69b29 (opens source in a new tab)
Valsartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption In healthy volunteers, valsartan peak plasma concentration is reached 2 hours to 4 hours after dosing.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=1600Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.